Idelalisib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted idelalisib, while AWMSG (Wales) did not recommend it.
Assessment has run over 6 years, from 29 Jan 2015 at AWMSG (Wales) to 13 Jan 2021 at NYE METODER (Norway).
NYE METODER (Norway) changed its position: recommended on 15 Nov 2015, not recommended by 22 Apr 2020.
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for idelalisib, 1 submission was never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
The programme is broad: 13 distinct indication wordings are recorded for idelalisib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
11 of these 30 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
The systems moved almost together: all 8 agencies opened a file on idelalisib within a year of one another, starting with AWMSG (Wales) on 29 Jan 2015.
Activity is concentrated rather than steady: 13 of 30 dated records fall in 2015 alone.
7 of the 8 agencies here assessed idelalisib more than once, PBAC (Australia) most often at 11 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for idelalisib.
The full ledger for idelalisib reads 10 recommended, 4 other, 4 deferred and 3 restricted, with 9 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 13 Jan 2021 | Kombinasjon med rituksimab og bendamustin til behandling av kronisk lymfatisk leukemi hos pasienter som har fått minst e… | decision recorded | source |
| PBAC (Australia) | 2020 | Chronic lymphocytic leukaemia and small lymphocytic lymphoma | Chronic lymphocytic leukaemia and small lymphocytic lymphoma: | The PBAC noted that ibruti… | source |
| NICE (England) | 2 Oct 2019 | NICE TA604 | terminated appraisal | source |
| HAS (France) | 7 Jun 2017 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 3 Apr 2017 | Treatment of adult patients with follicular lymphoma that is refractory to two prior lines of treatment | superseded (full) | source |
25 further decisions for idelalisib, across 8 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- pirtobrutinib — divergent outcome (recommended vs not recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
Coverage: 30 decisions for idelalisib from 8 agencies, 2015 to 2021. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.